

MAY. 18. 2006 11:54AM

AVENTIS US PAT DEPT

RECEIVED  
CENTRAL FAX CENTER

NO. 4182 P. 15

MAY 18 2006

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
Strobel H. et al.

Examiner: Powers, Fiona

Art Unit: 1626

Application No.: 10/634,979

Filed: August 5, 2003

Title: Acylamino-Substituted Heteroaromatic  
Compounds And Their Use As Pharmaceuticals

**Certificate of Mailing or Transmission**  
I hereby certify that this correspondence is being deposited  
with the United States Postal Service with sufficient postage  
for first class mail in an envelope addressed to the Mail Stop  
Amendment address below, or being facsimile transmitted to  
the USPTO, on the date indicated below.  
Date of Deposit May 18, 2006  
Printed Name of Person Signing Certificate Renee McGinnis  
Signature Renee McGinnis


**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED**

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Enclosed is a Supplemental Information Disclosure Statement for which the fee specified in  
37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00. The Commissioner is  
authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-  
1982.

Respectfully submitted,

  
\_\_\_\_\_  
Jiang Lin, Reg. No. 51,065  
Attorney/Agent for Applicant

sanofi-aventis Inc. LLC  
U.S. Patent Operations  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-3582  
Telefax (908) 231-2626

sanofi-aventis Docket No. DEAV2002/0056 US NP

MAY 18 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of  
STROBEL, et al.

Examiner: Powers, Fiona

Application No.: 10/634,979

Art Unit: 1626


Filed: August 5, 2003

## TELEFAX CERTIFICATE

Title: ACYLAMINO-SUBSTITUTED HETEROAROMATIC  
COMPOUNDS AND THEIR USE AS PHARMACEUTICALS .I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, on

May 18, 2006

Date of Transmission

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☐ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.


- ☒ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☒ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Pursuant to 37 C.F.R. § 1.98, Applicants submit a concise explanation of the relevance of the non-English-language patent reference FR 2121394 listed on the attached PTO-1449 form:

- FR 2121394 discloses 2-methylindole-3-carboxylic acid amide derivatives.

Enclosed for the Examiner's convenience is a copy of the Chemical Abstract's summary of FR 2121394.

Respectfully submitted,



Jiang Lin, Reg. No. 51,065  
Agent for Applicants

Sanofi-aventis U.S. LLC.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3582  
Telefax (908) 231-2626  
Aventis Docket No. DEAV2002/0056 US NP



